More Evidence Ozempic Can Curb Alcoholism

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 12, 2025.

By Ernie Mundell HealthDay Reporter

WEDNESDAY, Feb. 12, 2025 -- Yet another study is supporting the notion that the blockbuster GLP-1 drug Ozempic can help problems drinkers curb their intake.

The research found that, compared to placebo, weekly injections of semaglutide (also marketed for weight loss as Wegovy) helped reduce cravings in people with alcohol use disorders. The drug also seemed to reduce the quantity and frequency of alcohol intake, researchers said.

There's a real need for new approaches to treat alcoholism, said study lead author Christian Hendershot. He directs clinical research at the University of Southern California's Institute for Addiction Research.

“Two drugs currently approved to reduce alcohol consumption aren’t widely used," Hendershot said in a university news release. "The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder."

His team published its findings Feb. 12 in JAMA Psychiatry.

Links between GLP-1 meds and reductions in alcohol dependence aren't new: Patients taking GLP-1s for diabetes or weight loss quickly realized their appetite for booze fell after commencing the therapy.

However, Hendershot called the new study the first randomized, placebo-controlled clinical trial to investigate this effect.

The trial involved 48 adult problem drinkers who were otherwise not actively seeking treatment to cut down on their drinking.

Female participants drank more than seven drinks per week, while men drank 14 or more weekly. All of the participants also engaged in two or more heavy drinking episodes (four or more drinks for women and five or more for men) per week.

A week prior to the study, the USC team had participants drink the alcoholic beverage of their choice in a controlled setting, to set a baseline for their typical cravings and consumption.

The study itself involved weekly, low-dose injections of Ozempic or a placebo for nine weeks, during which time people's weekly drinking habits were also measured.

When the study ended, participants went back to the lab to again assess how much booze they might consume.

As noted in other studies, Ozempic seemed tied to reductions in the number of cravings folks had and the number of drinks they consumed. These reductions seemed to outpace those observed with drugs already approved to treat problem drinking, Hendershot's team noted.

Heavy-drinking days were also greatly reduced: By the end of the trial, 40% of the people taking Ozempic said they'd had no days of heavy drinking over the last month of treatment, compared to 20% of those who took a placebo.

A smaller subset of the drinkers also smoked, and the research showed that smoking rates declined among those taking Ozempic.

“These data suggest the potential of semaglutide and similar drugs to fill an unmet need for the treatment of alcohol use disorder,” concluded study senior author Dr. Klara Klein.

“Larger and longer studies in broader populations are needed to fully understand the safety and efficacy in people with alcohol use disorder, but these initial findings are promising," said Klein, an assistant professor of medicine at the University of North Carolina at Chapel Hill.

See Does Ozempic work for Alcohol Use Disorder (AUD)? for more information.

Sources

  • University of Southern California, news release, Feb. 12, 2025

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2025-02-13 06:00

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords